NSAID-induced  ||| S:0 E:14 ||| FW
urticaria ||| S:14 E:23 ||| FW
/ ||| S:23 E:24 ||| FW
angioedema  ||| S:24 E:35 ||| FW
does  ||| S:35 E:40 ||| VBZ
not  ||| S:40 E:44 ||| RB
evolve  ||| S:44 E:51 ||| VB
into  ||| S:51 E:56 ||| IN
chronic  ||| S:56 E:64 ||| JJ
urticaria ||| S:64 E:73 ||| NN
:  ||| S:73 E:75 ||| :
a  ||| S:75 E:77 ||| DT
12-year  ||| S:77 E:85 ||| JJ
follow-up  ||| S:85 E:95 ||| JJ
study  ||| S:95 E:101 ||| NN
Nonsteroidal  ||| S:101 E:114 ||| NNP
anti-inflammatory  ||| S:114 E:132 ||| JJ
drugs  ||| S:132 E:138 ||| NNS
( ||| S:138 E:139 ||| -LRB-
NSAIDs ||| S:139 E:145 ||| NNP
)  ||| S:145 E:147 ||| -RRB-
are  ||| S:147 E:151 ||| VBP
the  ||| S:151 E:155 ||| DT
most  ||| S:155 E:160 ||| RBS
frequent  ||| S:160 E:169 ||| JJ
medicaments  ||| S:169 E:181 ||| NNS
involved  ||| S:181 E:190 ||| VBN
in  ||| S:190 E:193 ||| IN
drug  ||| S:193 E:198 ||| NN
hypersensitivity  ||| S:198 E:215 ||| NN
reactions ||| S:215 E:224 ||| NNS
,  ||| S:224 E:226 ||| ,
with  ||| S:226 E:231 ||| IN
NSAID-induced  ||| S:231 E:245 ||| FW
urticaria ||| S:245 E:254 ||| FW
/ ||| S:254 E:255 ||| FW
angioedema  ||| S:255 E:266 ||| FW
( ||| S:266 E:267 ||| -LRB-
NIUA ||| S:267 E:271 ||| NNP
)  ||| S:271 E:273 ||| -RRB-
being  ||| S:273 E:279 ||| VBG
the  ||| S:279 E:283 ||| DT
most  ||| S:283 E:288 ||| RBS
frequent  ||| S:288 E:297 ||| JJ
clinical  ||| S:297 E:306 ||| JJ
entity ||| S:306 E:312 ||| NN
.  ||| S:312 E:314 ||| .
The  ||| S:314 E:318 ||| DT
natural  ||| S:318 E:326 ||| JJ
evolution  ||| S:326 E:336 ||| NN
of  ||| S:336 E:339 ||| IN
NIUA  ||| S:339 E:344 ||| NNP
has  ||| S:344 E:348 ||| VBZ
been  ||| S:348 E:353 ||| VBN
suggested  ||| S:353 E:363 ||| VBN
to  ||| S:363 E:366 ||| TO
lead  ||| S:366 E:371 ||| VB
to  ||| S:371 E:374 ||| TO
chronic  ||| S:374 E:382 ||| JJ
urticaria  ||| S:382 E:392 ||| NNS
( ||| S:392 E:393 ||| -LRB-
CU ||| S:393 E:395 ||| NNP
)  ||| S:395 E:397 ||| -RRB-
in  ||| S:397 E:400 ||| IN
an  ||| S:400 E:403 ||| DT
important  ||| S:403 E:413 ||| JJ
proportion  ||| S:413 E:424 ||| NN
of  ||| S:424 E:427 ||| IN
patients ||| S:427 E:435 ||| NNS
,  ||| S:435 E:437 ||| ,
such  ||| S:437 E:442 ||| JJ
that  ||| S:442 E:447 ||| IN
NIUA  ||| S:447 E:452 ||| NNP
may  ||| S:452 E:456 ||| MD
therefore  ||| S:456 E:466 ||| RB
precede  ||| S:466 E:474 ||| VB
CU ||| S:474 E:476 ||| NNP
.  ||| S:476 E:478 ||| .
Our  ||| S:478 E:482 ||| PRP$
aim  ||| S:482 E:486 ||| NN
was  ||| S:486 E:490 ||| VBD
to  ||| S:490 E:493 ||| TO
verify  ||| S:493 E:500 ||| VB
whether  ||| S:500 E:508 ||| IN
these  ||| S:508 E:514 ||| DT
entities  ||| S:514 E:523 ||| NNS
are  ||| S:523 E:527 ||| VBP
related  ||| S:527 E:535 ||| VBN
by  ||| S:535 E:538 ||| IN
following  ||| S:538 E:548 ||| VBG
up  ||| S:548 E:551 ||| RP
a  ||| S:551 E:553 ||| DT
large  ||| S:553 E:559 ||| JJ
cohort  ||| S:559 E:566 ||| NN
of  ||| S:566 E:569 ||| IN
patients  ||| S:569 E:578 ||| NNS
with  ||| S:578 E:583 ||| IN
NIUA  ||| S:583 E:588 ||| NNP
as  ||| S:588 E:591 ||| IN
well  ||| S:591 E:596 ||| RB
as  ||| S:596 E:599 ||| IN
a  ||| S:599 E:601 ||| DT
control  ||| S:601 E:609 ||| NN
group  ||| S:609 E:615 ||| NN
over  ||| S:615 E:620 ||| IN
a  ||| S:620 E:622 ||| DT
long  ||| S:622 E:627 ||| JJ
period  ||| S:627 E:634 ||| NN
of  ||| S:634 E:637 ||| IN
time ||| S:637 E:641 ||| NN
.  ||| S:641 E:643 ||| .
The  ||| S:643 E:647 ||| DT
study  ||| S:647 E:653 ||| NN
comprised  ||| S:653 E:663 ||| VBD
three  ||| S:663 E:669 ||| CD
groups ||| S:669 E:675 ||| NNS
:  ||| S:675 E:677 ||| :
( ||| S:677 E:678 ||| -LRB-
i ||| S:678 E:679 ||| FW
)  ||| S:679 E:681 ||| -RRB-
patients  ||| S:681 E:690 ||| NNS
with  ||| S:690 E:695 ||| IN
a  ||| S:695 E:697 ||| DT
confirmed  ||| S:697 E:707 ||| JJ
history  ||| S:707 E:715 ||| NN
of  ||| S:715 E:718 ||| IN
NIUA  ||| S:718 E:723 ||| NNP
( ||| S:723 E:724 ||| -LRB-
more  ||| S:724 E:729 ||| JJR
than  ||| S:729 E:734 ||| IN
two  ||| S:734 E:738 ||| CD
episodes  ||| S:738 E:747 ||| NNS
with  ||| S:747 E:752 ||| IN
at  ||| S:752 E:755 ||| IN
least  ||| S:755 E:761 ||| JJS
two  ||| S:761 E:765 ||| CD
different  ||| S:765 E:775 ||| JJ
NSAIDs  ||| S:775 E:782 ||| JJ
or  ||| S:782 E:785 ||| CC
positive  ||| S:785 E:794 ||| JJ
drug  ||| S:794 E:799 ||| NN
provocation  ||| S:799 E:811 ||| NN
tests ||| S:811 E:816 ||| NNS
) ||| S:816 E:817 ||| -RRB-
,  ||| S:817 E:819 ||| ,
( ||| S:819 E:820 ||| -LRB-
ii ||| S:820 E:822 ||| LS
)  ||| S:822 E:824 ||| -RRB-
patients  ||| S:824 E:833 ||| NNS
with  ||| S:833 E:838 ||| IN
more  ||| S:838 E:843 ||| JJR
than  ||| S:843 E:848 ||| IN
two  ||| S:848 E:852 ||| CD
episodes  ||| S:852 E:861 ||| NNS
of  ||| S:861 E:864 ||| IN
urticaria ||| S:864 E:873 ||| CD
/ ||| S:873 E:874 ||| CD
angioedema  ||| S:874 E:885 ||| NN
to  ||| S:885 E:888 ||| TO
a  ||| S:888 E:890 ||| DT
single  ||| S:890 E:897 ||| JJ
NSAID  ||| S:897 E:903 ||| NN
with  ||| S:903 E:908 ||| IN
good  ||| S:908 E:913 ||| JJ
tolerance  ||| S:913 E:923 ||| NN
to  ||| S:923 E:926 ||| TO
a  ||| S:926 E:928 ||| DT
strong  ||| S:928 E:935 ||| JJ
COX-1  ||| S:935 E:941 ||| CD
inhibitor  ||| S:941 E:951 ||| NNS
and ||| S:951 E:954 ||| CC
/ ||| S:954 E:955 ||| NNP
or  ||| S:955 E:958 ||| CC
evidence  ||| S:958 E:967 ||| NN
by  ||| S:967 E:970 ||| IN
in  ||| S:970 E:973 ||| IN
vivo  ||| S:973 E:978 ||| JJ
tests  ||| S:978 E:984 ||| NNS
supporting  ||| S:984 E:995 ||| VBG
specific  ||| S:995 E:1004 ||| JJ
IgE  ||| S:1004 E:1008 ||| JJ
antibodies  ||| S:1008 E:1019 ||| NNS
to  ||| S:1019 E:1022 ||| TO
the  ||| S:1022 E:1026 ||| DT
drug  ||| S:1026 E:1031 ||| NN
( ||| S:1031 E:1032 ||| -LRB-
single  ||| S:1032 E:1039 ||| FW
NSAID-induced  ||| S:1039 E:1053 ||| FW
urticaria ||| S:1053 E:1062 ||| FW
/ ||| S:1062 E:1063 ||| FW
angioedema ||| S:1063 E:1073 ||| FW
,  ||| S:1073 E:1075 ||| ,
SNIUA ||| S:1075 E:1080 ||| NNP
) ||| S:1080 E:1081 ||| -RRB-
,  ||| S:1081 E:1083 ||| ,
and  ||| S:1083 E:1087 ||| CC
( ||| S:1087 E:1088 ||| -LRB-
iii ||| S:1088 E:1091 ||| LS
)  ||| S:1091 E:1093 ||| -RRB-
controls  ||| S:1093 E:1102 ||| VBZ
who  ||| S:1102 E:1106 ||| WP
tolerated  ||| S:1106 E:1116 ||| VBP
NSAIDs ||| S:1116 E:1122 ||| JJ
.  ||| S:1122 E:1124 ||| .
All  ||| S:1124 E:1128 ||| DT
cases  ||| S:1128 E:1134 ||| NNS
in  ||| S:1134 E:1137 ||| IN
the  ||| S:1137 E:1141 ||| DT
three  ||| S:1141 E:1147 ||| CD
groups  ||| S:1147 E:1154 ||| NNS
were  ||| S:1154 E:1159 ||| VBD
followed  ||| S:1159 E:1168 ||| VBN
up  ||| S:1168 E:1171 ||| RP
over  ||| S:1171 E:1176 ||| IN
a  ||| S:1176 E:1178 ||| DT
period  ||| S:1178 E:1185 ||| NN
of  ||| S:1185 E:1188 ||| IN
12 years ||| S:1188 E:1196 ||| CD
.  ||| S:1196 E:1198 ||| .
There  ||| S:1198 E:1204 ||| EX
were  ||| S:1204 E:1209 ||| VBD
190  ||| S:1209 E:1213 ||| CD
patients  ||| S:1213 E:1222 ||| NNS
with  ||| S:1222 E:1227 ||| IN
NIUA  ||| S:1227 E:1232 ||| NNP
( ||| S:1232 E:1233 ||| -LRB-
64.6 ||| S:1233 E:1237 ||| NNP
%  ||| S:1237 E:1239 ||| NN
female ||| S:1239 E:1245 ||| NN
;  ||| S:1245 E:1247 ||| :
mean  ||| S:1247 E:1252 ||| JJ
age  ||| S:1252 E:1256 ||| NN
43.71 ± 15.82 years ||| S:1256 E:1275 ||| NN
,  ||| S:1275 E:1277 ||| ,
110  ||| S:1277 E:1281 ||| CD
with  ||| S:1281 E:1286 ||| IN
SNIUA ||| S:1286 E:1291 ||| NNP
,  ||| S:1291 E:1293 ||| ,
and  ||| S:1293 E:1297 ||| CC
152  ||| S:1297 E:1301 ||| CD
controls ||| S:1301 E:1309 ||| NNS
.  ||| S:1309 E:1311 ||| .
At  ||| S:1311 E:1314 ||| IN
the  ||| S:1314 E:1318 ||| DT
12-year  ||| S:1318 E:1326 ||| JJ
evaluation ||| S:1326 E:1336 ||| NN
,  ||| S:1336 E:1338 ||| ,
12  ||| S:1338 E:1341 ||| CD
patients  ||| S:1341 E:1350 ||| NNS
with  ||| S:1350 E:1355 ||| IN
NIUA  ||| S:1355 E:1360 ||| NNP
( ||| S:1360 E:1361 ||| -LRB-
6.15 ||| S:1361 E:1365 ||| CD
% ||| S:1365 E:1366 ||| NN
)  ||| S:1366 E:1368 ||| -RRB-
had  ||| S:1368 E:1372 ||| VBD
developed  ||| S:1372 E:1382 ||| VBN
CU  ||| S:1382 E:1385 ||| NNP
over  ||| S:1385 E:1390 ||| IN
a  ||| S:1390 E:1392 ||| DT
1-  ||| S:1392 E:1395 ||| NN
to  ||| S:1395 E:1398 ||| TO
8-year  ||| S:1398 E:1405 ||| CD
period ||| S:1405 E:1411 ||| NN
.  ||| S:1411 E:1413 ||| .
Similar  ||| S:1413 E:1421 ||| JJ
proportions  ||| S:1421 E:1433 ||| NNS
were  ||| S:1433 E:1438 ||| VBD
seen  ||| S:1438 E:1443 ||| VBN
in  ||| S:1443 E:1446 ||| IN
SNIUA  ||| S:1446 E:1452 ||| NNP
and  ||| S:1452 E:1456 ||| CC
controls ||| S:1456 E:1464 ||| NNS
.  ||| S:1464 E:1466 ||| .
Nonsteroidal  ||| S:1466 E:1479 ||| FW
anti-inflammatory  ||| S:1479 E:1497 ||| FW
drugs-induced  ||| S:1497 E:1511 ||| FW
urticaria ||| S:1511 E:1520 ||| FW
/ ||| S:1520 E:1521 ||| FW
angioedema  ||| S:1521 E:1532 ||| FW
does  ||| S:1532 E:1537 ||| VBZ
not  ||| S:1537 E:1541 ||| RB
seem  ||| S:1541 E:1546 ||| VB
to  ||| S:1546 E:1549 ||| TO
precede  ||| S:1549 E:1557 ||| VB
the  ||| S:1557 E:1561 ||| DT
onset  ||| S:1561 E:1567 ||| NN
of  ||| S:1567 E:1570 ||| IN
CU  ||| S:1570 E:1573 ||| NNP
over  ||| S:1573 E:1578 ||| IN
the  ||| S:1578 E:1582 ||| DT
medium  ||| S:1582 E:1589 ||| NN
term ||| S:1589 E:1593 ||| NN
.  ||| S:1593 E:1595 ||| .
Further  ||| S:1595 E:1603 ||| JJ
research  ||| S:1603 E:1612 ||| NN
including  ||| S:1612 E:1622 ||| VBG
a  ||| S:1622 E:1624 ||| DT
longer  ||| S:1624 E:1631 ||| JJR
follow-up  ||| S:1631 E:1641 ||| NN
is  ||| S:1641 E:1644 ||| VBZ
necessary  ||| S:1644 E:1654 ||| JJ
to  ||| S:1654 E:1657 ||| TO
verify  ||| S:1657 E:1664 ||| VB
this  ||| S:1664 E:1669 ||| DT
observation ||| S:1669 E:1680 ||| NN
.  ||| S:1680 E:1682 ||| .
